Chicago Capital LLC Has $17.35 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Chicago Capital LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 35,762 shares of the medical research company’s stock after selling 1,774 shares during the quarter. Chicago Capital LLC’s holdings in Thermo Fisher Scientific were worth $17,345,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TMO. Elevation Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. S.A. Mason LLC raised its position in Thermo Fisher Scientific by 7.0% during the third quarter. S.A. Mason LLC now owns 319 shares of the medical research company’s stock worth $155,000 after acquiring an additional 21 shares in the last quarter. Lafayette Investments Inc. grew its position in shares of Thermo Fisher Scientific by 2.4% in the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 22 shares during the period. Finally, Diversified Enterprises LLC increased its stake in shares of Thermo Fisher Scientific by 1.6% during the 3rd quarter. Diversified Enterprises LLC now owns 1,411 shares of the medical research company’s stock worth $684,000 after purchasing an additional 22 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Leerink Partners lifted their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Wells Fargo & Company raised their price objective on Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Citigroup raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $580.00 to $660.00 in a research report on Thursday, December 11th. Finally, UBS Group upped their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $619.60.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $611.23 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $611.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The firm has a market cap of $229.65 billion, a price-to-earnings ratio of 35.31, a P/E/G ratio of 3.90 and a beta of 0.91. The stock’s fifty day moving average price is $576.92 and its two-hundred day moving average price is $512.10.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the company posted $5.28 earnings per share. Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a stock buyback program on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Frederick M. Lowery sold 6,912 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the sale, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. This represents a 32.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michel Lagarde sold 22,046 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the completion of the transaction, the chief operating officer directly owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. This trade represents a 20.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 149,271 shares of company stock valued at $86,507,282 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.